HUE025948T2 - Eljárás metasztázis gátlására a karcinogenézis õssejt fúziós modelljében - Google Patents

Eljárás metasztázis gátlására a karcinogenézis õssejt fúziós modelljében Download PDF

Info

Publication number
HUE025948T2
HUE025948T2 HUE11165870A HUE11165870A HUE025948T2 HU E025948 T2 HUE025948 T2 HU E025948T2 HU E11165870 A HUE11165870 A HU E11165870A HU E11165870 A HUE11165870 A HU E11165870A HU E025948 T2 HUE025948 T2 HU E025948T2
Authority
HU
Hungary
Prior art keywords
cells
cell
tumor
fusion
cancer
Prior art date
Application number
HUE11165870A
Other languages
English (en)
Inventor
David T Harris
Tom C Tsang
Xianghui He
Brian L Pipes
Linda C Meade-Tollin
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Publication of HUE025948T2 publication Critical patent/HUE025948T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (4)

Szabadalmi Igénypontok
1, Készítmény tumor metasztázis kezelést eljárásban történő alkalmazásra miáltal a tumor sejt migrációja gátolt, amely készítmény öbíquítín elleni antitest hatékony mennyiségét tartalmazza, ahol az antitest nem IV1EL-14.
2, Az 1. igénypont szerinti készítmény tumor metasztázis kezelési eljárásban történő alkalmazásra miáltal a tumor sejt migrációja gátolt, ahol a tumor fuziónált sejtét tartalmaz,
3, Az 1, igénypont szerinti készítmény tumor metasztázis kezelési eljárásban történő alkalmazásra miáltal a tumor sejt migrációja gátolt, ahol az antitestet az alábbi antitestek csoportjából választjuk: 14372 és 10C2-2.
4 ín vitro eljárás tumor sejt migrációjának gátlására, amely az alábbiakat foglalja magában: egy tumor tumor sejtjének érintkezésbe hozása egy ubiquítin elleni antitest hatékony mennyiségével, ahol az antitest nem MEL-14, 3, A 4. igénypont szerinti eljárás, amely továbbá az érintkezésbe hozás előtt a tumorban egy fuzionált sejt jelenlétének megerősítésének lépését tartalmazza, δ, A 4, igénypont szerinti eljárás, ahol az antitestet az alábbi antitestek csoportjából választjuk: 14372 és 10C2-2,
HUE11165870A 2005-08-25 2006-08-25 Eljárás metasztázis gátlására a karcinogenézis õssejt fúziós modelljében HUE025948T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71124905P 2005-08-25 2005-08-25

Publications (1)

Publication Number Publication Date
HUE025948T2 true HUE025948T2 (hu) 2016-05-30

Family

ID=37772481

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11165870A HUE025948T2 (hu) 2005-08-25 2006-08-25 Eljárás metasztázis gátlására a karcinogenézis õssejt fúziós modelljében

Country Status (16)

Country Link
US (2) US8158126B2 (hu)
EP (2) EP2363146B1 (hu)
JP (2) JP5400381B2 (hu)
KR (2) KR101413055B1 (hu)
CN (2) CN101273124B (hu)
AU (2) AU2006282853B2 (hu)
BR (1) BRPI0615081A2 (hu)
CA (2) CA2620616C (hu)
ES (2) ES2523857T3 (hu)
HK (1) HK1161976A1 (hu)
HU (1) HUE025948T2 (hu)
IL (2) IL189674A (hu)
RU (1) RU2404805C2 (hu)
SG (1) SG152229A1 (hu)
WO (1) WO2007025216A2 (hu)
ZA (1) ZA200802512B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60017888T2 (de) 1999-04-05 2006-01-19 Emisphere Technologies, Inc. Dinatrium-salze, monohydrate und ethanol-solvate
CA2620616C (en) * 2005-08-25 2016-06-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Stem cell fusion model of carcinogenesis
US20120295344A1 (en) * 2006-08-25 2012-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Stem Cell Fusion Model of Carcinogenesis
BRPI0616558B1 (pt) 2005-09-19 2021-09-08 Emisphere Technologies, Inc Forma i do sal dissódico do ácido n-(5-clorossaliciloil)-5-aminocapróico, monohidrato cristalino do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, forma ii do sal dissódico do ácido n-(5-clorossaliciloil)-5-aminocapróico, solvato de etanol cristalino do sal dissódico do ácido n-(5-salicioloil)-8-aminocaprílico, forma iii do sal dissódico do ácido n-(5-clorossaliciloil)-5- aminocapróico, octahidrato do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, monohidrato cristalino do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, composição farmacêutica, processo para preparar a forma i do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, processo para preparar um solvato de monoetanol do sal dissódico do ácido n-(5-saliciloil)-8-(...)
KR101538521B1 (ko) 2005-12-15 2015-07-22 제넨테크, 인크. 폴리유비퀴틴 표적화를 위한 방법 및 조성물
CN101977934B (zh) 2008-01-18 2014-09-17 健泰科生物技术公司 用于靶向k63连接的多聚遍在蛋白的方法和组合物
CN101760452B (zh) * 2008-11-18 2012-12-19 中国科学院上海生命科学研究院 一种胚胎干细胞和肿瘤细胞的杂合细胞系及其构建方法
US8178307B2 (en) * 2009-09-02 2012-05-15 National Tsing Hua University Methods and compositions for detection of lethal cell and uses thereof
WO2011130499A1 (en) 2010-04-15 2011-10-20 Genentech, Inc. Anti-polyubiquitin antibodies and methods of use
JP6320756B2 (ja) 2010-12-06 2018-05-09 キュア キャンサー ワールドワイド エルエルシー 癌を治療するための化学および免疫療法を用いた癌細胞の代謝標的法
BR112014002716A2 (pt) 2011-08-05 2017-06-13 Genentech Inc anticorpos anti-poliubiquitina e métodos de uso
CN110391025A (zh) * 2018-04-19 2019-10-29 清华大学 一种面向宏微观多维度胃癌早期风险评估的人工智能建模方法
US11052041B1 (en) 2020-10-01 2021-07-06 King Abdulaziz University Nanotechnology-based nostril drops for relief of respiratory ailments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04504501A (ja) * 1988-12-23 1992-08-13 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ホーミング配列およびそれらの使用
US6007816A (en) 1989-03-17 1999-12-28 Fred Hutchinson Cancer Research Center Methods of using CD44-specific antibodies
WO1994021294A1 (en) * 1993-03-19 1994-09-29 Bigner Darell D Method of treating tumors with antibodies
AU718140B2 (en) 1995-10-17 2000-04-06 Dovetail Technologies, Inc. Low molecular weight cell, bone marrow and immune stimulants
AU782952C (en) * 1999-08-25 2006-09-07 Altarex Medical Corp. Therapeutic immune condition compositions and methods
EP1619950A4 (en) * 2003-04-18 2006-08-02 Univ Massachusetts PROGNOSIS, DIAGNOSIS AND TREATMENT OF BONE MARROW DERIVED FROM STEM CELLS ASSOCIATED WITH CANCER
CN1302102C (zh) * 2003-12-29 2007-02-28 中国医学科学院血液学研究所 通过扩增巨核祖细胞和成熟巨核细胞制备巨核细胞制剂的方法及用途
US20060033366A1 (en) 2004-08-11 2006-02-16 Jeffrey Vernon M Headrest display device
AU2006272780A1 (en) * 2005-07-22 2007-02-01 The Regents Of The University Of California Heparin compostions and selectin inhibition
CA2620616C (en) * 2005-08-25 2016-06-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Stem cell fusion model of carcinogenesis

Also Published As

Publication number Publication date
ES2523857T3 (es) 2014-12-02
IL222468A (en) 2015-10-29
HK1161976A1 (en) 2012-08-17
AU2006282853A1 (en) 2007-03-01
AU2011201605B2 (en) 2012-12-20
KR101413055B1 (ko) 2014-07-02
CA2808168A1 (en) 2007-03-01
ZA200802512B (en) 2009-01-28
EP2363146B1 (en) 2015-06-24
IL189674A0 (en) 2008-06-05
EP2363146A1 (en) 2011-09-07
WO2007025216A2 (en) 2007-03-01
CN101273124B (zh) 2013-05-08
CA2620616A1 (en) 2007-03-01
CN103212071B (zh) 2017-12-12
EP1924685B1 (en) 2014-08-27
KR20130020738A (ko) 2013-02-27
EP1924685A2 (en) 2008-05-28
IL189674A (en) 2012-10-31
EP1924685A4 (en) 2009-03-04
CA2808168C (en) 2018-06-12
ES2552101T3 (es) 2015-11-25
US20120201808A1 (en) 2012-08-09
JP2009505664A (ja) 2009-02-12
CN101273124A (zh) 2008-09-24
RU2008111144A (ru) 2009-09-27
RU2404805C2 (ru) 2010-11-27
JP2011225613A (ja) 2011-11-10
WO2007025216A3 (en) 2007-07-05
KR20080048499A (ko) 2008-06-02
AU2006282853B2 (en) 2011-01-20
JP5400381B2 (ja) 2014-01-29
KR101413048B1 (ko) 2014-06-30
US8158126B2 (en) 2012-04-17
US8758755B2 (en) 2014-06-24
AU2011201605A1 (en) 2011-04-28
JP5597171B2 (ja) 2014-10-01
SG152229A1 (en) 2009-05-29
BRPI0615081A2 (pt) 2011-05-03
CA2620616C (en) 2016-06-14
US20090016961A1 (en) 2009-01-15
CN103212071A (zh) 2013-07-24

Similar Documents

Publication Publication Date Title
AU2006282853B2 (en) Stem cell fusion model of carcinogenesis
Wang et al. Pre-clinical study of human umbilical cord mesenchymal stem cell transplantation for the treatment of traumatic brain injury: safety evaluation from immunogenic and oncogenic perspectives
CN102477445A (zh) 荧光素酶的慢病毒载体表达系统及其用途
CN103237887A (zh) 胚胎干细胞来源的心肌细胞以及包含所述心肌细胞作为活性成分的细胞治疗剂
CN110172442B (zh) 一种人诱导多潜能干细胞、构建方法及其用途
US20140308297A1 (en) Stem Cell Fusion Model of Carcinogenesis
CN113817777B (zh) 来源于人的先天性巨大黑痣良性肿瘤细胞系及其构建方法
Kumar et al. Isolation of tumor cells based on their distance from blood vessels
Lauder et al. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology
KR20200121316A (ko) Icam-1 마커 및 이의 응용
US20200108091A1 (en) Gut-protective effect of rig-1/mavs and sting activation
Crawford et al. Isolation, Purification, and Culture of Embryonic Melanoblasts from Green Fluorescent Protein–expressing Reporter Mice
KR20230087559A (ko) 정상 핵형을 갖는 신규한 nr1 es-유래 신경 줄기세포 및 이의 용도
CN117838860A (zh) 一种抑制周围神经侵袭的药物、药物组合物、联合用药物